결핵 진료지침

Med 2020;382:893–902.
29. Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, et al. Bedquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis. N Engl J Med 2022;387:810–23.
30. Nyang’wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al. A 24-week, all-oral regimen for rifampin-resistant tuberculosis. N Engl J Med 2022;387:2331–43.
31. Tyagi S, Ammerman NC, Li SY, Adamson J, Converse PJ, Swanson RV, et al. Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis. Proc Natl Acad Sci U S A 2015;112:869–74.
32. Grosset JH, Tyagi S, Almeida DV, Converse PJ, Li SY, Ammerman NC, et al. Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am J Respir Crit Care Med 2013;188:608–12.
33. Swanson RV, Ammerman NC, Ngcobo B, Adamson J, Moodley C, Dorasamy A, et al. Clofazimine contributes sustained antimicrobial activity after treatment cessation in a mouse model of tuberculosis chemotherapy. Antimicrob Agents Chemother 2016;60:2864–9.
34. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010;182:684–92.
35. Tang S, Yao L, Hao X, Liu Y, Zeng L, Liu G, et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis 2015;60:1361–7.
36. Dalcolmo M, Gayoso R, Sotgiu G, D’Ambrosio L, Rocha JL, Borga L, et al. Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil. Eur Respir J 2017;49:1602445.
37. Cegielski JP, Chan PC, Lan Z, Udwadia ZF, Viiklepp P, Yim JJ, et al.

III. 약제내성결핵의 치료 135
<PAGE>135